Sequential nephron blockade versus sequential renin–angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study
暂无分享,去创建一个
J. Ménard | G. Chatellier | S. Laurent | P. Boutouyrie | G. Bobrie | P. Plouin | M. Azizi | S. Peyrard | M. Frank
[1] Bryan Williams,et al. Management of hypertension: summary of NICE guidance , 2011, BMJ : British Medical Journal.
[2] J. Václavík,et al. Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT): A Randomized, Double-Blind, Placebo-Controlled Trial , 2011, Hypertension.
[3] B. Álvarez-Álvarez,et al. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin–angiotensin–aldosterone system , 2010, Journal of hypertension.
[4] B. Psaty,et al. Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction. , 2010, JAMA.
[5] E. Muxfeldt,et al. Efficacy of Spironolactone Therapy in Patients With True Resistant Hypertension , 2010, Hypertension.
[6] M. Moser,et al. Use of diuretics in patients with hypertension. , 2009, The New England journal of medicine.
[7] B. Imholz,et al. Aldosterone-receptor antagonism in hypertension , 2009, Journal of hypertension.
[8] G. Bakris,et al. Resistant hypertension: an overview of evaluation and treatment. , 2008, Journal of the American College of Cardiology.
[9] Daniel W. Jones,et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. , 2008, Circulation.
[10] J. Ménard,et al. Teletransmission of home blood pressure monitoring: making it easier. , 2008, Journal of hypertension.
[11] S. Yusuf,et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.
[12] A. Dominiczak,et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. , 2007, Journal of hypertension.
[13] F. Zannad. Aldosterone antagonist therapy in resistant hypertension , 2007, Journal of hypertension.
[14] M. Moser,et al. Resistant or Difficult-to-Control Hypertension , 2006 .
[15] M. Moser,et al. Clinical practice. Resistant or difficult-to-control hypertension. , 2006, The New England journal of medicine.
[16] W. Ambrosius,et al. Improvement in Blood Pressure With Inhibition of the Epithelial Sodium Channel in Blacks With Hypertension , 2005, Hypertension.
[17] G. MacGregor,et al. Systematic Review of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blockade in Hypertension , 2005, Hypertension.
[18] J. Ménard,et al. REFRACTORY HYPERTENSION: EFFICACY AND SAFETY OF A TRIPLE DIURETIC ASSOCIATION , 2004 .
[19] J. Ménard,et al. Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists , 2004, Circulation.
[20] Daniel W. Jones,et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.
[21] J. Ménard,et al. Dual renin–angiotensin system blockade restores blood pressure–renin dependency in individuals with low renin concentrations , 2003, Journal of hypertension.
[22] Thomas Lumley,et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. , 2003, JAMA.
[23] Gnana Bharathy,et al. Upregulation of Na+ transporter abundances in response to chronic thiazide or loop diuretic treatment in rats. , 2003, American journal of physiology. Renal physiology.
[24] S. Nielsen,et al. Sodium transporter abundance profiling in kidney: effect of spironolactone. , 2002, American journal of physiology. Renal physiology.
[25] François Gueyffier,et al. J-Shaped Relationship between Blood Pressure and Mortality in Hypertensive Patients: New Insights from a Meta-Analysis of Individual-Patient Data , 2002, Annals of Internal Medicine.
[26] F. Magrini,et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension , 2001, Journal of hypertension.
[27] P. Meneton,et al. Differential subcellular localization of ENaC subunits in mouse kidney in response to high- and low-Na diets. , 2000, American journal of physiology. Renal physiology.
[28] G. Parati,et al. Task force IV: Clinical use of ambulatory blood pressure monitoring. Participants of the 1999 Consensus Conference on Ambulatory Blood Pressure Monitoring. , 1999, Blood pressure monitoring.
[29] J. Laragh,et al. β-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects , 1999 .
[30] J. Laragh,et al. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. , 1999, American journal of hypertension.
[31] E. Mutschler,et al. Sequential nephron blockade breaks resistance to diuretics in edematous states. , 1997, Journal of cardiovascular pharmacology.
[32] J. Hall,et al. Role of the renin-angiotensin system in control of sodium excretion and arterial pressure. , 1990, Acta physiologica Scandinavica. Supplementum.
[33] G. Mancia,et al. Clinical use of ambulatory blood pressure monitoring. , 1989, American journal of hypertension.
[34] J. Ménard,et al. Efficacy and tolerance of spironolactone in essential hypertension. , 1987, The American journal of cardiology.
[35] J. Staessen,et al. Double-blind comparison between propranolol and bendroflumethiazide in captopril-treated resistant hypertensive patients. , 1983, American heart journal.
[36] F. Finnerty. Diuretics as initial treatment for essential hypertension. , 1979, British journal of clinical pharmacology.
[37] J. Laragh,et al. The renin axis and vasoconstriction volume analysis for understanding and treating renovascular and renal hypertension. , 1975, The American journal of medicine.